glimepiride has been researched along with Fibrosis in 1 studies
glimepiride: structure given in first source
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonalcoholic fatty liver disease (NAFLD) is a liver phenotype of type 2 diabetes and obesity." | 7.11 | Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. ( Arai, K; Goto, H; Harada, K; Honda, M; Iida, N; Kaneko, S; Kita, Y; Mizukoshi, E; Nakamura, H; Nakano, Y; Takamura, T; Takata, N; Takeshita, Y; Tanaka, T; Tsujiguchi, H; Yamashita, T, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) is a liver phenotype of type 2 diabetes and obesity." | 3.11 | Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. ( Arai, K; Goto, H; Harada, K; Honda, M; Iida, N; Kaneko, S; Kita, Y; Mizukoshi, E; Nakamura, H; Nakano, Y; Takamura, T; Takata, N; Takeshita, Y; Tanaka, T; Tsujiguchi, H; Yamashita, T, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takeshita, Y | 1 |
| Honda, M | 1 |
| Harada, K | 1 |
| Kita, Y | 1 |
| Takata, N | 1 |
| Tsujiguchi, H | 1 |
| Tanaka, T | 1 |
| Goto, H | 1 |
| Nakano, Y | 1 |
| Iida, N | 1 |
| Arai, K | 1 |
| Yamashita, T | 1 |
| Mizukoshi, E | 1 |
| Nakamura, H | 1 |
| Kaneko, S | 1 |
| Takamura, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver[NCT02649465] | Phase 4 | 40 participants (Actual) | Interventional | 2015-11-11 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for glimepiride and Fibrosis
| Article | Year |
|---|---|
Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Humans; Inflammation; Liver; | 2022 |